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Abstract
Introduction Recombinant human soluble thrombomodulin
(rhsTM) is newly developed for the treatment of DIC. The
purpose of this study was to evaluate the efficacy of the
concomitant administration of rhsTM and antithrombin (AT).
Methods In the first series, rats were treated with either 62.5,
125, 250 or 500 IU/kg (n = 6, each) of AT or 0.125, 0.25, 0.5
or 1.0 mg/kg (n = 6, each) of rhsTM followed by
lipopolysaccharide (LPS) injection. 8 h later, the fibrinogen level
was examined. In the second series, TM group was pretreated
with 0.25 mg/kg of rhsTM, AT group was pretreated with 125
IU/kg of AT, AT/TM group was pretreated with both AT and
rhsTM, and control group was pretreated with saline (n = 7,
each). The platelet count, fibrinogen, ALT, LDH and high-
mobility group box 1 (HMGB1) levels were measured. In
addition, histologic changes in liver were examined. In the third
series, survival was calculated up to 24 h.
Results Both AT and rhsTM produced a linear dose-response
with regard to the fibrinogen level, with 125 IU/kg of AT and
0.25 mg/kg of rhsTM producing equivalent effects. The
combined administration of AT and rhsTM significantly reduced
the decrease in the platelet count and the fibrinogen level (P <
0.05, 0.01, respectively). The elevations in ALT and LDH were
significantly suppressed in all treatment groups. The HMGB1
level and the histologic changes tended to indicate damage
reduction. Survival was significantly better only in AT/TM group
(P < 0.01).
Conclusions The coadministration of AT and rhsTM might be
effective for the treatment of severe sepsis.
Introduction
The tight cross-talk between the coagulation system and
inflammatory reactions during sepsis has attracted much
attention and anticoagulant therapies have been expected to
be beneficial not only for septic coagulopathy but also for
severe sepsis [1-3]. Two major physiological anticoagulant
systems, the activated protein C (APC)-thrombomodulin (TM)
system and the antithrombin (AT)-heparan sulphate system,
have been extensively studied as research targets.
APC is best known for its natural anticoagulant properties, and
a multi-center randomized controlled trial (RCT) previously
demonstrated the efficacy of recombinant human APC against
severe sepsis [4]; thus, the application of recombinant human
APC has been strongly recommended in an international
guideline for the treatment of severe sepsis [5]. TM, a cell sur-
face-expressed glycoprotein, is predominantly synthesized by
vascular endothelial cells, and is a critical cofactor for the
thrombin-mediated activation of protein C (PC). A recom-
binant human soluble TM (rhsTM) has been recently devel-
oped [6], and this new agent has some advantages over APC
such as a long in vivo half-life and a unique amino-terminal
structure exhibiting anti-inflammatory activity including
sequestration [7] and cleavage of high-mobility group box 1
ALT: alanine aminotransferase; APC: activated protein C; AT: antithrombin; DIC: disseminated intravascular coagulation; ELISA: enzyme-linked immu-
nosorbent assay; H&E: hematoxylin and eosin; HMGB1: high-mobility group box 1; LDH: lactate dehydrogenase; LPS: lipopolysaccharide; RCT: ran-
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(HMGB1) [8], recently identified as a lethal late-phase media-
tor and is suspected to be closely correlated with the develop-
ment of disseminated intravascular coagulation (DIC) during
sepsis [9]. Furthermore, its efficacy on the treatment of DIC
was confirmed in a recent RCT [10].
AT is another natural coagulant that has been extensively stud-
ied [11-14]. As the anticoagulant effects of the TM-APC sys-
tem are expressed through a different mechanism from that of
the AT-heparan sulphate system, the additive effects can be
reasonably expected. As a single drug is likely to be insuffi-
cient to improve the outcome of severe sepsis, the purpose of
this study was to examine whether the concomitant adminis-
tration of AT and rhsTM exerts additive effects resulting in bet-
ter survival in a sepsis model with DIC.
Materials and methods
Eight-week-old male Wistar rats (Japan SLC, Shizuoka, Japan)
were used in this study. All experimental procedures were con-
ducted after obtaining the approval of the Ethical Committee
for Animal Experiments of Juntendo University. All rats were
provided with standard rat chow and water ad libitum. The rats
were anesthetized with sodium pentobarbital (40 mg/kg, intra-
peritoneally), and systemic inflammation was induced by
administering a single injection of lipopolysaccharide (LPS;
L4130 0111:B4, Sigma Chemical Co., St. Louis, MO, USA)
via the caudal vein at a dose of 20 mg/kg.
Dose setting study
In the first series, a total of 54 rats were treated with either
saline alone (n = 6), human plasma-derived AT (Nihon Pharma-
ceutical Co., Osaka, Japan) at a dose of 62.5, 125, 250, or
500 IU/kg (n = 6, each dose) or rhsTM (ART-123, Asahi Kasei
Pharma Co., Tokyo, Japan) at a dose of 0.125, 0.25, 0.5, or
1.0 mg/kg (n = 6, each dose) followed by LPS injection. Eight
hours later, blood samples were obtained from the inferior
vena cava and the plasma fibrinogen level was measured
using clotting methods and the Automated Blood Coagulation
Analyzer CS-2000 i (Sysmex Co., Kobe, Japan). In addition to
the control and treatment groups, the plasma fibrinogen level
was also measured in normal rats (n = 6)
Co-administration study
In the second series, 28 animals were divided into four groups.
In the AT group (n = 7), 125 IU/kg of AT was intravenously
administered via the caudal vein before LPS injection. In the
TM group (n = 7), 0.25 mg/kg of rhsTM was intravenously
administered via the caudal vein before LPS injection. In the
AT/TM group (n = 7), 125 IU/kg of AT and 0.25 mg/kg of
rhsTM were intravenously administered before LPS injection.
In the control group (n = 7), animals were given saline alone
before the treatment of LPS. At eight hours after the LPS injec-
tion, rats were sacrificed under deep anesthesia in an ether
chamber. Blood samples were obtained from the inferior vena
cava, and the platelet count was determined using a multi-
automatic blood cell counter for animals (MICROS abc LC-
152, HORIBA, Ltd. Tokyo, Japan). Citrated plasma samples
Figure 1
Comparison of fibrinogen levels Comparison of fibrinogen levels. The plasma fibrinogen level decreased significantly decreased at eight hours after lipopolysaccharide (LPS) injec-
tion, and this decrease was suppressed by treatment with either antithrombin (AT) or thrombomodulin (TM) in a dose-dependent manner (n = 6, for 
each dose). The fibrinogen levels were 126.6 ± 11.1 mg/dL and 124.2 ± 14.7 mg/dL after pre-treatment with 125 IU/kg of AT and 0.25 mg/kg of 
TM, respectively. N = normal; C = control.
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obtained by whole blood centrifugation were stored at -80°C
until assay. The plasma fibrinogen level and the levels of the
organ damage markers alanine aminotransferase (ALT) and
lactate dehydrogenase (LDH) were measured in the samples.
The enzymatic activity of LDH was measured using an LDH-J
kit (Wako Chemicals, Osaka, Japan). In the same samples, the
HMGB1 level was measured using an ELISA kit (Shino-test,
Tokyo, Japan).
In the same series, a portion of the liver was excised and the
specimens were fixed in 10% buffered formalin, embedded in
paraffin, stained with H&E, and examined using light micros-
Figure 2
Changes in coagulation markers Changes in coagulation markers. The platelet count had decreased significantly at eight hour after lipopolysaccharide (LPS) injection in the control 
group (n = 7). This depletion was slightly suppressed in both the antithrombin (AT) and thrombomodulin (TM) groups (n = 7 each); however, the dif-
ferences were not statistically significant. Meanwhile, the platelet count in the AT/TM group was significantly higher in the AT/TM group (n = 7). Sim-
ilarly, the fibrinogen level was significantly depressed at eight hours after LPS injection in the control group (n = 7) and this depletion was 
suppressed in the AT and TM groups; however, the differences were not statistically significant. The level was best maintained in the AT/TM group 
(P < 0.01, n = 7). N = normal; C = control.
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Figure 3
Changes in organ dysfunction markers Changes in organ dysfunction markers. The elevated level of alanine aminotransferase (ALT) at eight hours after lipopolysaccharide (LPS) injection in 
the control group (n = 7) was significantly suppressed in the antithrombin (AT, n = 7, P < 0.01), recombinant human thrombomodulin (TM, n = 7, P 
< 0.05), and AT/TM groups (n = 7, P < 0.01). The elevated lactate dehydrogenase (LDH) level in the control group at eight hours was significantly 
suppressed in the AT and AT/TM groups (P < 0.01, each). N = normal; C = control.
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copy. In addition to the control and treatment groups, the same
measurement was performed in normal rats (n = 7).
Survival
In the third series, survival was calculated up to 24 hours after
LPS injection in the control (n = 23), AT (n = 22), TM (n = 22)
and AT/TM groups (n = 22).
Statistics
All data were expressed as the mean ± standard deviation. A
statistical analysis was carried out using the SAS program
(version 8.02, SAS Institute, Cary, North Carolina, USA). Com-
parison between the normal and control groups were exam-
ined using the Welch's t-test for non-parametric analysis.
Comparisons between the treatment groups and the control
group were carried out using the Dunnett's or Steel test. Sur-
vival was examined using a log-rank test. Statistical differences
were deemed significant at a level of P < 0.05.
Results
The dose setting study revealed the dose-response effects for
the maintenance of fibrinogen levels after LPS injection in both
the AT and rhsTM treatment groups. The plasma fibrinogen
level was 126.6 ± 11.1 mg/dL after treatment with125 IU/kg
of AT, or approximately half of the normal level; treatment with
0.25 mg/kg of rhsTM produced a comparable effect (Figure
1). Thus, 125 IU/kg of AT and 0.25 mg/kg of rhsTM was uti-
lized in subsequent studies.
In the co-administration study, the platelet counts and fibrino-
gen levels decreased significantly after LPS injection. These
reductions were suppressed in both the AT and rhsTM
groups; however; the differences were not statistically signifi-
cant in these groups. In contrast, the AT/TM group showed a
significant reduction in these haemostatic markers (P < 0.05
for the platelet count, P < 0.01 for the fibrinogen level; Figure
2).
The levels of ALT and LDH were significantly elevated after
LPS injection, and the elevation of ALT was significantly sup-
pressed in all the treatment groups (P < 0.05 in TM, P < 0.01
in AT and AT/TM; Figure 3, left). Similarly, the elevation of LDH
was significantly suppressed in the AT and AT/TM groups (P
< 0.01 in each group; Figure 3, right). However, a significant
difference was not recognized between the AT and AT/TM
groups.
The HMGB1 level exceeded 15.0 ng/mL at eight hours after
LPS injection. This elevation was suppressed in all the treat-
ment groups to a level approximately one-third of that in the
control group; however, the differences between each group
and the control group were not statistically significant (Figure
4).
The histological changes after LPS injection were character-
ized by inflammatory cell infiltration, hemorrhagic changes and
focal necrosis in the midzone and periportal regions of the liver
at eight hours after LPS injection. These histological altera-
tions were attenuated by pre-treatment with either AT, rhsTM
or a combination of AT and rhsTM. Although the histological
changes were not prominent, the changes were further con-
firmed by a serological analysis (Figure 5).
A Kaplan-Meier survival curve was calculated using data
obtained for a maximum of 24 hours after LPS injection; sur-
vival started to decrease beginning at 12 hours after LPS injec-
tion, and at 24 hours only 1 of 23 rats (4.4%) was alive in the
control group, whereas 7 of the 22 rats (31.8%) were still alive
in the AT/TM group; the difference between the groups was
significant (P < 0.01; Figure 6).
Discussion
Accumulating evidence suggest that many anticoagulants
have effects on inflammation [15]. For example, we previously
reported the efficacy of danaparoid sodium [16], recombinant
Figure 4
Changes in HMGB1 Changes in HMGB1. The high-mobility group box 1 (HMGB1) level 
increased at 8 h after the treatment of lipopolysaccharide (LPS) treat-
ment in the control group (n = 7). The levels were lower in antithrombin 
(AT, n = 7), recombinant human soluble thrombomodulin (TM, n = 7) 
and AT/TM groups (n = 7) and were approximately one-third of that in 
the control group; however, the differences were not rstatistically signif-
icant (P < 0.1, each). N = normal; C = control.
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APC [17] and AT [12] in a similar rat sepsis model. However,
none of these drugs achieved a satisfactory result and the
combined administration of antithrombotic agents may provide
a multipronged approach to the treatment of severe sepsis.
Consequently, we planned the present experiment to examine
the effects of a combination of AT and rhsTM.
With regard to the dose settings for both agents, because the
primary purpose of this study was not to compare AT and
rhsTM but to examine the additive effects of these agents, the
dose of AT was set at a relatively low value. Actually, we pre-
viously reported that a dose of 125 IU/kg of AT enabled recov-
ery to a value with the normal range and revealed the additive
effects of AT and danaparoid sodium [18].
The effects of rhsTM on DIC were previously examined in a
multi-center RCT, and the resolution of DIC was significantly
better in the group treated with rhsTM than in the group
treated with unfractionated heparin [11]. As the patients with
resolved DIC had a lower mortality rate in this RCT, the correc-
tion of the coagulation abnormalities was suggested to lead to
improved survival. In addition, other experiments reported that
the effects of rhsTM were not only limited to DIC but that ben-
eficial effects were also obtained against severe sepsis and
other inflammatory responses [19,20]. Therefore, a clinical trial
to determine the effects of rhsTM on severe sepsis is now
underway.
AT was expected to have favorable effects against severe sep-
sis, but it was denied in a large-scale multi-center RCT [11].
Figure 5
Histological analysis of the liver Histological analysis of the liver. Representative photographs (200× magnification; hematoxylin and eosin (H&E) stain) of liver sections taken eight 
hours after the injection of lipopolysaccharide (LPS) in partially hepatectomized rats that had been treated with saline (control), antithrombin (AT), 
recombinant human soluble thrombomodulin (TM), or AT and TM (AT/TM). The solid arrow points to leukocyte infiltration, and the hatched arrow 
points to necrotic hepatocytes.
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However, as a subgroup analysis reported beneficial effects in
septic DIC patients [13], Hoffmann and colleagues [14] per-
formed a small-sized RCT with an enrollment of 40 patients.
This study demonstrated a better maintenance of haemostatic
markers such as prothrombin time and fibrinogen level.
The mortality rate for severe sepsis is still high and a single
drug may be inadequate to obtain a favorable outcome [21];
therefore, we planned to examine the effects of the concomi-
tant use of AT and rhsTM. Theoretically, the combination of AT
and rhsTM could possibly exert additive or synergistic effects
because the anticoagulant mechanisms differ for these
agents. As a result, the changes of platelet count and the
fibrinogen levels were suppressed significantly only in the AT/
TM group. However, as for the improvement in the organ dys-
function markers, there was no statistically significant differ-
ence in the ALT or LDH levels between AT and AT/TM group
in this study. As for why we could not see the additive effects,
we speculate that because AT alone had already suppressed
the elevation of LDH significantly, and the effects of rhsTM
might be concealed.
With respect to the survival, it was better maintained in the AT/
TM group compared with that in the control group. However,
the significant difference was not seen between the AT group
and AT/TM group, or rhsTM group and AT/TM group.
The mechanism of action responsible for these effects was not
fully elucidated; however, other than the maintenance of coag-
ulation disorders, the exertion of anti-inflammatory effects may
contribute to the end result. To address this issue, the
changes in the HMGB1 level were examined. HMGB1 is an
intranuclear protein that was originally identified as a DNA-
binding protein, [22], but has been recognized as a late-phase
mediator during sepsis [23]. HMGB1 is also known to act as
a pro-coagulant [24] as well as a pro-inflammatory mediator for
septic organ dysfunction [25,26]. However, whether anticoag-
ulant therapy can regulate this so-called lethal mediator
remains uncertain [27,28]. Although the HMGB1 level tended
to decrease with AT and rhsTM pre-treatment in this study, the
role of this mechanism in organ protection and the improve-
ment in survival is still uncertain because the decrease was not
significant.
Other than the above mechanisms, as the pathologic findings
suggested a lower level of inflammatory cell infiltration and
necrotic changes after treatment, these mechanisms might
contribute to the maintenance of organ protection. However,
the changes were not remarkable probably because of the
early timing of the sampling, so further study is needed to clar-
ify the mechanism of action.
Conclusions
Although the additive effects of AT and rhsTM were recog-
nized with regard to the changes in coagulation markers, the
organ damage levels were similar among the AT, TM, and AT/
TM groups. Survival was significantly better in the AT/TM
group.
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